Literature DB >> 19012245

Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes.

L Pazzaglia1, A Chiechi, A Conti, G Gamberi, G Magagnoli, C Novello, L Morandi, P Picci, M Mercuri, M S Benassi.   

Abstract

Rhabdomyosarcoma, the most common soft tissue sarcoma in childhood, belongs to the small round cell tumor family and is classified according to its histopathological features as embryonal, alveolar and pleomorphic. In this study we propose to explore genetic alterations involved in rhabdomyosarcoma tumorigenesis and assess the level of mRNA gene expression of controlling survival signalling pathways. For genetic and molecular analysis, array-based comparative genomic hybridization, combined with Real Time PCR using the comparative method, was performed on 14 primary well-characterized human primary rhabdomyosarcomas. Multiple changes affecting chromosome arms were detected in all cases, including gain or loss of specific regions harbouring cancer progression-associated genes. Evaluation of mRNA levels showed in the majority of cases overexpression of MCL1 and MAP2K4 genes, both involved in cell viability regulation. Our findings on rhabdomyosarcoma samples showed multiple copy number alterations in chromosome regions implicated in malignancy progression and indicated a strong expression of MAP2K4 and MCL1 genes, both involved in different biological functions of complicated signalling pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19012245     DOI: 10.14670/HH-24.61

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  10 in total

1.  Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes.

Authors:  F Basit; S Cristofanon; S Fulda
Journal:  Cell Death Differ       Date:  2013-06-07       Impact factor: 15.828

2.  MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.

Authors:  Xiaozhen Wu; Zuode Gong; Lanying Sun; Long Ma; Qibao Wang
Journal:  Cell Prolif       Date:  2017-03-20       Impact factor: 6.831

3.  Laryngeal embryonal rhabdomyosarcoma in an adult - a case presentation in the eyes of geneticists and clinicians.

Authors:  Wojciech Kukwa; Piotr Wojtowicz; Beata Jagielska; Grzegorz Sobczyk; Andrzej Kukwa; Anna M Czarnecka
Journal:  BMC Cancer       Date:  2011-05-12       Impact factor: 4.430

4.  ABT-737 suppresses aberrant Hedgehog pathway and overcomes resistance to smoothened antagonists by blocking Gli.

Authors:  Wenjing Huang; Han Liu; Wenfu Tan; Juan Wang
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

5.  Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.

Authors:  Ellen Preuss; Manuela Hugle; Romy Reimann; Marcel Schlecht; Simone Fulda
Journal:  J Biol Chem       Date:  2013-10-16       Impact factor: 5.157

6.  Cell death pathways as therapeutic targets in rhabdomyosarcoma.

Authors:  Simone Fulda
Journal:  Sarcoma       Date:  2012-01-12

7.  Embryonal Rhabdomyosarcoma of the Adult's Vocal Cord: A Case Report.

Authors:  Yining Li; Zhongying Fu; Weilun Chen; Lixin Yang; Wei Zhu
Journal:  Iran Red Crescent Med J       Date:  2015-08-26       Impact factor: 0.611

8.  MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment.

Authors:  Clara Alcon; Fernando Martín; Estela Prada; Jaume Mora; Aroa Soriano; Gabriela Guillén; Soledad Gallego; Josep Roma; Josep Samitier; Alberto Villanueva; Joan Montero
Journal:  Cell Death Discov       Date:  2022-04-07

Review 9.  Translational research in diagnosis and management of soft tissue tumours.

Authors:  Eugenio Rimondi; Maria Serena Benassi; Alberto Bazzocchi; Alba Balladelli; Giancarlo Facchini; Giuseppe Rossi; Sophie Taieb; Daniel Vanel
Journal:  Cancer Imaging       Date:  2016-06-07       Impact factor: 3.909

10.  Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.

Authors:  Clara Alcon; Albert Manzano-Muñoz; Estela Prada; Jaume Mora; Aroa Soriano; Gabriela Guillén; Soledad Gallego; Josep Roma; Josep Samitier; Alberto Villanueva; Joan Montero
Journal:  Cell Death Dis       Date:  2020-08-15       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.